At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 52 enrolled
Drug / intervention
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhalerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Investigator Initiated, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Glycopyrrolate/Formoterol on Exercise Tolerance and Dynamic Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease.
In Brief
A Phase 4 clinical trial evaluating Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The objective of the study is to determine if a dual inhaled bronchodilator (Glycopyrrolate/Formoterol) is effective in increasing exercise time relative to placebo in patients with Chronic Obstructive Pulmonary Disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMar 2017
Primary CompletionJan 2019
Study CompletionJan 2019
TodayJul 2026
First PostedMar 16, 2017
Enrollment StartMar 27, 2017
Primary CompletionJan 1, 2019
Study CompletionJan 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.3 years ago
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhalerdrug
Exercise Tolerance